stella
beta
68Ga-FAPI-46 PET/CT for Predicting Histological Response in Triple-negative Breast Cancer (FAP-IT) — Stella
Home
/
Triple Negative Breast Cancer
/
68Ga-FAPI-46 PET/CT for Predicting Histological Response in Triple-negative Breast Cancer (FAP-IT)
View on ClinicalTrials.gov
Recruiting
Back to Triple Negative Breast Cancer trials
68Ga-FAPI-46 PET/CT for Predicting Histological Response in Triple-negative Breast Cancer (FAP-IT)
Not a traditional drug trial — this study doesn't follow the standard phase structure.
Trial locations
(6 sites)
France
Hôpital Privé d'Antony, Antony
Institut Curie -site Paris, Paris
GH Diaconesses Croix Saint-Simon, Paris
Institut Curie -site St Cloud, Saint-Cloud
HIA Begin, Saint-Mandé
Hôpital FOCH, Suresnes